DocumentRX-9165
Issued
Read4 min

FDA rejects ivonescimab, greenlights Roche's Wilserdly in November oncology wave

FDA rejects Summit's ivonescimab over missing OS data, approves Roche's Wilserdly; phase 3 wins for CG Oncology and Sellas; $350M for Dren Bio and Lilly's $1.5B Calytrix buy.

TAG C-4460 · 700 words on the filing

Oncology biotech news: Key moves to watch in November 2026
Oncology biotech news: Key moves to watch in November 2026ckstockphoto / pixabay

Summary of findings

  • FDA issued a CRL for ivonescimab, citing no statistically significant overall survival benefit
  • Cretostimogene cut NMIBC recurrence risk 68% after 17 months of phase 3 follow-up
  • Sellas' GPS vaccine cut AML death risk 41%; median OS 24 vs 14.7 months in 126 patients
  • Dren Bio raised $350M; Boehringer's SBP deal carries $358M upfront and $7B in milestones
  • Lilly is buying Calytrix Bio for up to $1.5B and partnered with Stipple Bio for up to $5.9B

The FDA handed Summit Therapeutics a complete response letter for ivonescimab in November's most consequential oncology decision, weeks after approving Roche's oral SERD Wilserdly — just two moves in a month that spanned eight headline developments from mid-October onwards.

What did the FDA decide on ivonescimab?

The agency refused approval of the PD-1xVEGF bispecific in combination with platinum chemotherapy for locally advanced or metastatic NSCLC in patients previously treated with EGFR TKIs. Regulators determined substantial evidence of effectiveness isn't established without a statistically significant overall survival improvement, and said a PFS benefit alone doesn't support a positive benefit-risk profile.

Chairman and co-CEO Robert W. Duggan pushed back: "With five positive phase 3 studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab's development." Summit continues multiregional phase 2 or 3 trials in NSCLC, colorectal cancer, urothelial carcinoma and renal cell carcinoma.

Which approvals and readouts moved the needle?

Roche's Wilserdly (giredestrant) secured FDA approval for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. It's the first next-generation all-oral SERD combination to beat standard endocrine combination therapy in a head-to-head phase 3 trial in the post-CDK4/6 inhibitor setting. Up to 40% of HR-positive metastatic breast cancer patients develop ESR1 mutations driving resistance. The FDA is also reviewing the drug in the adjuvant setting, with a decision due by end of November — approval would make it the first SERD cleared for both adjuvant and advanced disease.

CG Oncology's intravesical oncolytic immunotherapy cretostimogene grenadenorepvec met its primary endpoint in a phase 3 trial in intermediate-risk and high-grade non-muscle invasive bladder cancer, cutting recurrence risk by 68% versus control after 17 months of follow-up. No FDA-approved adjuvant options exist in that setting. The company sees the asset as a potential "backbone" therapy. Its first BLA in BCG-unresponsive NMIBC — now broadened to cover CIS and high-grade papillary-only disease per FDA feedback — is expected to complete in March 2027, with a second BLA supported by the new data anticipated in Q2 2027.

Sellas Life Sciences' off-the-shelf vaccine galinpepimut-S (GPS), targeting WT1-bearing residual leukemia cells, hit its primary endpoint in a 126-patient phase 3 AML study. It reduced the risk of death by 41%, with median overall survival of 24 months versus 14.7 months on best available treatment. President and CEO Angelos Stergiou said the company looks "forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible." BLA preparations are underway.

Where did the money flow?

Dren Bio closed an oversubscribed $350 million private financing to push dibotatug — a CD94-targeting monoclonal antibody that selectively depletes pathogenic cytotoxic cells — through late-stage development, regulatory submission and planned launch in cytotoxic T-cell lymphoma and large granular lymphocytic leukemia. Phase 1/2 data across more than 300 patients showed high overall and complete response rates in relapsed/refractory disease with favorable tolerability. Both indications lack approved therapies.

Eli Lilly made two moves. It's acquiring Calytrix Bio for up to $1.5 billion, gaining a biparatopic antibody against mCALR-driven essential thrombocythemia and myelofibrosis — designed for pan-mutant, disease-modifying activity in a field where current drugs mostly manage symptoms. Lilly also signed a multi-target research and license deal with Stipple Bio, whose Pointillist Platform identifies tumor-specific cell surface epitope binders. Stipple receives an upfront payment plus equity and stands to earn up to $5.9 billion in milestones; Lilly takes exclusive worldwide rights.

Boehringer Ingelheim and SBP Group struck a multi-program option and license agreement covering six preclinical biologic programs built on ADC and T-cell engager technologies — five from LaNova Medicines, one from Beijing Tide Pharmaceutical. SBP companies receive $358 million upfront and near-term, with $7 billion in potential milestones. Boehringer can exercise options for ex-China rights on four programs and worldwide rights on two after agreed clinical milestones.

via Labiotech.eu (Source)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

10 articles

Linked filings

  1. T-7165
  2. C-7166
  3. K-1065
  4. P-9899
  5. P-6323

Next filing »